Language·English

Lieping Chen is the United Technologies Corporation Professor in Cancer Research and Professor of Immunobiology, of Dermatology and of Medcine (Medical Oncology);Co-Director, Cancer Immunology Program at Yale Cancer Center.

 

With his pioneering research on tumor immunotherapy, Dr. Lieping Chen has revolutionized cancer treatment and jump-started the modern era of cancer immunotherapy. His work laid the foundation for the development for all immune checkpoint inhibitors that arecurrently approved for patient treatment, including anti-CTLA4, anti-PD-1 and anti-PD-L1 antibodies.  These have been shown to be the most effective and safest cancer treatments and have saved many lives, especially of late-stage patients with cancers resistant to conventional treatments or with extensive metastasis. 

 

The effectiveness of anti-PD-1/PD-L1 antibodies has been demonstrated in more than 25 solid and hematological tumors, with an average response rate of 30%, and with 10% of patients in complete remission. More than 90% of responding late stage cancer patients benefited from anti-PD-1/PD-L1 treatments in immunological therapy.

 

Because of his discovery of the PD-L1/PD-1 pathway in tumor immune escape, and his seminal work in the antibody blockade of PD=1/PD-L1 pathway as a cancer therapy, Dr. Lieping Chen’s research was named the most important scientific breakthrough of 2013 by Science Magazine. Dr. Chen has also received numerous other awards, including the William B. Coley Award -- the highest award in immunology -- in 2014, and the Warren Alpert Foundation Prize in 2017; he was the third Chinese winner, after geneticist Yuewei Jian and chemist Youyou Tu.

    · SCBA Presidential Award, Society of Chinese Bioscientists in America (2017)

    · Warren Alpert Foundation Prize, Warren Alpert Foundation/Harvard Medical School (2017)

    · Biomedical Sciences Award, Boao Forum Asia in Biomedical Sciences (2017)

    · Shizhang Bei International Award, The Biophysical Society of China (2017)

    · CAST-US Innovation Award, Chinese Association for Science and Technology USA (2016)

    · AAI-Steinman Award, American Association of Immunologists (2016)

    · CAHON-Lifetime Achievement Award, CAHON (2015)

    · William B. Coley Award, Cancer Research Institute (2014)

    · Inaugural United Technologies Corporation Endowed Chair Professor, Yale University (2013)

    · Honorary Master of Arts, Yale University (2012)

Edit: TAYU HUAXIA Group Author: Ekaterina Pesheva Date: June 6, 2017 The original link: https://hms.harvard.edu/news/warren-alpert-foundation-honors-pioneers-cancer-immunolog   Scientists recognized for seminal discoveries in cancer’s ability to thwart immune surveillance that paved the way to immune-based cancer therapies By EKATERINA PESHEVA, June 6, 2017 The 2017 Warren Alper ...
· SCBA Presidential Award, Society of Chinese Bioscientists in America (2017)· Warren Alpert Foundation Prize, Warren Alpert Foundation/Harvard Medical School (2017)· Biomedical Sciences Award, Boao Forum Asia in Biomedical Sciences (2017)· Shizhang Bei International Award, The Biophysical Society of China (2017)· CAST-US Innovation Award, Chinese Association for Science and T ...


隐私保护 新浪公司 版权所有 京ICP证000007
客户服务热线:4006900000 违法和不良信息举报电话:010-62675637 举报邮箱:jubao@vip.sina.com


京网文[2014]2045-295号 互联网新闻信息服务许可
国家药监局(京)-经营性-2014-0004 京教研[2002]7号 电信业务审批[2001]字第379号
增值电信业务经营许可证B2-20090108 电信与信息服务业务经营许可证000007号 京卫网审[2015]第0749号
广播电视节目制作经营许可证(京)字第828号 甲测资字1100078 京公网安备11000002000016号